文献速递免疫规划传染病防控与疫情报告

工程化侵入性乳酸乳球菌口服疫苗平台对婴儿利什曼原虫感染的控制

Engineered invasive Lactococcus lactis as an oral vaccine delivery platform is associated with compartmentalized immune modulation and enhances control of Leishmania infantum infection.
PubMed 文献 · Vaccine · 2026-10-02

本研究评估表达纤连蛋白结合蛋白A(FnBPA)并携带TryPan嵌合抗原质粒的工程化侵入性乳酸乳球菌作为口服疫苗递送平台,与皮下注射重组TryPan加单磷酰脂质A(MPLA)进行比较。口服侵入性乳酸乳球菌伴随肠道趋化因子、Th1/Th17相关细胞因子及炎症细胞标志物的变化,并调节全身免疫参数。婴儿利什曼原虫攻击后,口服携带TryPan构建体的乳酸乳球菌使肝脏寄生虫负荷较相应感染对照降低约99%;单用乳酸乳球菌也降低肝脏寄生虫负荷。皮下免疫重组TryPan加MPLA诱导更广泛的全身细胞因子反应,肝脏寄生虫负荷降低约90%。

要点

  • 口服侵入性乳酸乳球菌递送TryPan抗原使肝脏寄生虫负荷降低约99%。
  • 单用乳酸乳球菌亦降低肝脏寄生虫负荷,提示载体本身有免疫调节贡献。
  • 皮下重组TryPan加MPLA诱导更广泛全身细胞因子反应,寄生虫负荷降低约90%。

核心结论

  • 侵入性乳酸乳球菌作为口服疫苗递送平台具有控制肝脏婴儿利什曼原虫负荷的潜力,其效果与细菌载体相关免疫调节和抗原递送均有关。

研究设计与样本

  • 研究评估工程化侵入性乳酸乳球菌(表达FnBPA并携带TryPan嵌合抗原质粒)口服免疫,并与皮下免疫重组TryPan加MPLA进行比较,进行婴儿利什曼原虫攻击实验。

主要发现

  • 口服侵入性乳酸乳球菌伴随肠道趋化因子表达、Th1/Th17相关细胞因子及炎症细胞标志物变化,并调节全身免疫参数。
  • 婴儿利什曼原虫攻击后,口服携带TryPan构建体的乳酸乳球菌使肝脏寄生虫负荷较相应感染对照降低约99%。
  • 单用乳酸乳球菌也降低肝脏寄生虫负荷,提示细菌载体对寄生虫学结果有贡献。
  • 皮下免疫重组TryPan加MPLA诱导更广泛的全身细胞因子反应,肝脏寄生虫负荷降低约90%。
  • 多变量分析识别出不同免疫策略下黏膜、全身和肝脏参数之间不同的关联模式。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Visceral leishmaniasis caused by Leishmania infantum remains a major challenge for vaccine development due to the intracellular localization of the parasite and the need for effective antigen delivery and cellular immune responses. Genetically engineered lactic acid bacteria have emerged as promising platforms for mucosal vaccination because of their genetic tractability and capacity to interact with the host immune system. Here, we evaluated an engineered invasive Lactococcus lactis strain expressing fibronectin-binding protein A (FnBPA) and carrying the chimeric TryPan antigen-encoding plasmid as an oral vaccine delivery platform, and compared its immunological and parasitological outcomes with subcutaneous immunization using recombinant TryPan formulated with monophosphoryl lipid A (MPLA). Oral administration of invasive L. lactis was associated with changes in intestinal chemokine expression, Th1/Th17-associated cytokines, and inflammatory cell markers, together with modulation of systemic immune parameters. Following L. infantum challenge, oral administration of L. lactis carrying the TryPan construct resulted in an approximately 99% reduction in hepatic parasite burden compared with the corresponding infected control. Notably, administration of L. lactis alone also reduced hepatic parasite burden, indicating a contribution of the bacterial vector to the observed parasitological outcome, while the greater reduction observed with TryPan delivery suggests an additional effect associated with the vaccine construct. Subcutaneous immunization with recombinant TryPan and MPLA induced broader systemic cytokine responses and reduced hepatic parasite burden by approximately 90%. Multivariate analysis identified distinct patterns of association among mucosal, systemic, and hepatic parameters according to the vaccination strategy. Together, these findings support the potential of invasive L. lactis as an oral vaccine delivery platform and highlight the contribution of both bacterial-vector-associated immunomodulation and antigen delivery to the observed control of hepatic L. infantum burden.

来源:Vaccine,查看原文。版权归原作者所有。

引用

  1. Rihs JB, Duval IB, Amorim CCO, et al. Engineered invasive Lactococcus lactis as an oral vaccine delivery platform is associated with compartmentalized immune modulation and enhances control of Leishmania infantum infection. Vaccine. 2026. PMID: 42826691. doi:10.1016/j.vaccine.2026.129218

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。